DE69920732D1 - Bicyclische stickstoffheteroaryl verbindungen - Google Patents

Bicyclische stickstoffheteroaryl verbindungen

Info

Publication number
DE69920732D1
DE69920732D1 DE69920732T DE69920732T DE69920732D1 DE 69920732 D1 DE69920732 D1 DE 69920732D1 DE 69920732 T DE69920732 T DE 69920732T DE 69920732 T DE69920732 T DE 69920732T DE 69920732 D1 DE69920732 D1 DE 69920732D1
Authority
DE
Germany
Prior art keywords
lower alkyl
heteroaryl
aryl
cycloalkyl
theroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920732T
Other languages
English (en)
Other versions
DE69920732T2 (de
Inventor
William Harris
Huw Hill
Edward Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69920732(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823277.0A external-priority patent/GB9823277D0/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE69920732D1 publication Critical patent/DE69920732D1/de
Publication of DE69920732T2 publication Critical patent/DE69920732T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Inorganic Insulating Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69920732T 1998-10-23 1999-10-13 Bicyclische stickstoffheteroaryl verbindungen Expired - Fee Related DE69920732T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9823277.0A GB9823277D0 (en) 1998-10-23 1998-10-23 Bicycle nitrogen heterocycles
GB9823277 1998-10-23
GB9920044 1999-08-24
GBGB9920044.6A GB9920044D0 (en) 1998-10-23 1999-08-24 Biciclic nitrogen heterocycles
PCT/EP1999/007675 WO2000024744A1 (en) 1998-10-23 1999-10-13 Bicyclic nitrogen heterocycles

Publications (2)

Publication Number Publication Date
DE69920732D1 true DE69920732D1 (de) 2004-11-04
DE69920732T2 DE69920732T2 (de) 2006-02-23

Family

ID=26314565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920732T Expired - Fee Related DE69920732T2 (de) 1998-10-23 1999-10-13 Bicyclische stickstoffheteroaryl verbindungen

Country Status (25)

Country Link
US (1) US6150373A (de)
EP (1) EP1123295B1 (de)
JP (1) JP3593035B2 (de)
CN (1) CN1150195C (de)
AT (1) ATE277931T1 (de)
AU (1) AU769989B2 (de)
BR (1) BR9914677A (de)
CA (1) CA2347474C (de)
CZ (1) CZ20011394A3 (de)
DE (1) DE69920732T2 (de)
ES (1) ES2228123T3 (de)
HK (1) HK1041483B (de)
HR (1) HRP20010274A2 (de)
HU (1) HUP0104199A3 (de)
ID (1) ID28276A (de)
MA (1) MA27678A1 (de)
MY (1) MY126478A (de)
NO (1) NO318802B1 (de)
NZ (1) NZ510760A (de)
PL (1) PL347432A1 (de)
PT (1) PT1123295E (de)
RU (1) RU2256662C2 (de)
TR (1) TR200101102T2 (de)
TW (1) TWI227235B (de)
WO (1) WO2000024744A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
SK17532000A3 (sk) 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
EP1112070B1 (de) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Neue substituierte triazolverbindungen
JP2002528506A (ja) * 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
HUP0203564A3 (en) * 1999-10-21 2004-07-28 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
BR0014973A (pt) * 1999-10-21 2002-07-16 Hoffmann La Roche Ag G Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
DE60015599T2 (de) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (de) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Neues trisubstitutiertes 8H-Pyrido[2,3-d]pyrimidin-7-onderivat zur Behandlung von durch CSBP/p38kinase vermittelten Krankheiten
CA2441177A1 (en) 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
DE10235312A1 (de) * 2002-08-01 2004-02-12 Basf Ag Verfahren zur Herstellung von Aminoalkoxybenzylaminen und Aminoalkoxybenzonitrilen als Zwischenprodukte
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
ATE452121T1 (de) * 2003-04-23 2010-01-15 Japan Tobacco Inc Casr-antagonist
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
EP2583678A3 (de) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner Moleküle und Assays für deren Nachweis
BRPI0514750A (pt) * 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
CA2576818A1 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
EP3943087A1 (de) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroarylverbindungen und verwendungen davon
MX2015011514A (es) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
RS56924B9 (sr) 2013-04-19 2019-09-30 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3177295A4 (de) 2014-08-08 2018-06-13 Dana Farber Cancer Institute, Inc. Verwendungen von hemmern der salzinduzierbaren kinase (sik)
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
US10308656B2 (en) * 2015-08-18 2019-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of Ku70/80 and uses thereof
CN110225914A (zh) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
RU2019129727A (ru) * 2017-02-28 2021-03-30 Зэ Дженерал Хоспитал Корпорэйшн Применения пиримидопиримидинонов в качестве ингибиторов sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
CA3087886A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
EP3788047A2 (de) 2018-05-04 2021-03-10 Incyte Corporation Feste formen eines fgfr-inhibitors und verfahren zur herstellung davon
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
AR115296A1 (es) * 2018-12-27 2020-12-16 Agios Pharmaceuticals Inc Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220274991A1 (en) * 2019-07-16 2022-09-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
IL297714A (en) * 2020-04-28 2022-12-01 Iomx Therapeutics Ag Bicyclic kinase inhibitors and their uses
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (de) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Kondensierte polycyclische 2-aminopyrimidinderivate, ihre herstellung und verwendung als proteininhibitoren von tyrosinkinase
SK17532000A3 (sk) * 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze

Also Published As

Publication number Publication date
ATE277931T1 (de) 2004-10-15
NO318802B1 (no) 2005-05-09
MA27678A1 (fr) 2006-01-02
NZ510760A (en) 2003-08-29
CN1324360A (zh) 2001-11-28
JP2002528455A (ja) 2002-09-03
TWI227235B (en) 2005-02-01
WO2000024744A1 (en) 2000-05-04
ES2228123T3 (es) 2005-04-01
DE69920732T2 (de) 2006-02-23
CA2347474A1 (en) 2000-05-04
CN1150195C (zh) 2004-05-19
HUP0104199A3 (en) 2002-12-28
NO20011929L (no) 2001-04-19
BR9914677A (pt) 2001-07-17
ID28276A (id) 2001-05-10
EP1123295B1 (de) 2004-09-29
MY126478A (en) 2006-10-31
HRP20010274A2 (en) 2002-06-30
NO20011929D0 (no) 2001-04-19
CZ20011394A3 (cs) 2001-12-12
HK1041483B (zh) 2004-12-24
TR200101102T2 (tr) 2002-01-21
PT1123295E (pt) 2005-01-31
EP1123295A1 (de) 2001-08-16
RU2256662C2 (ru) 2005-07-20
HK1041483A1 (en) 2002-07-12
AU769989B2 (en) 2004-02-12
JP3593035B2 (ja) 2004-11-24
CA2347474C (en) 2008-08-26
US6150373A (en) 2000-11-21
HUP0104199A2 (hu) 2002-04-29
PL347432A1 (en) 2002-04-08
AU1036300A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
DE69920732D1 (de) Bicyclische stickstoffheteroaryl verbindungen
WO2005047290A3 (en) Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
NO995006L (no) Nye forbindelser
FI945706A0 (fi) Proteiinikinaasi C-inhibiittoreita
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
DE60006541D1 (de) Src-kinase hemmende verbindungen
MXPA02005844A (es) Inhibidores de cinasas de proteina.
CA2309551A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
WO2004016614A3 (en) Pyrrolopyrazines as kinase inhibitors
WO2002090332A3 (en) Novel aeylheteroalkylaminε derivatives
SE9803518D0 (sv) Novel compounds
SE9701304D0 (sv) Compounds
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
ATE389655T1 (de) Pyrimidinderivate
SE9803773D0 (sv) Compounds
WO2002083622A3 (en) Novel aminophenyl ketone derivatives
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
YU29301A (sh) Biciklična azotna heterociklična jedinjenja
PL375697A1 (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ATE324368T1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
WO2002074735A3 (de) Biurethanderivate
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee